Genome-Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case-Control Study

Prostate

Volumn 77, Issue 5, 2017, Pages 471-478

  FitzGerald, Liesel M ^a,b   Naeem, Haroon ^c   Makalic, Enes ^c   Schmidt, Daniel F ^c   Dowty, James G ^c   Joo, Jihoon E ^d   Jung, Chol Hee ^d   Bassett, Julie K ^a   Dugue, Pierre Antoine ^a   Chung, Jessica ^d   Lonie, Andrew ^d   Milne, Roger L ^a,c   Wong, Ee Ming ^d   Hopper, John L ^c   English, Dallas R ^a,c   Severi, Gianluca ^a,e,f,g   Baglietto, Laura ^a,e   Pedersen, John ^h   Giles, Graham G ^a,c   Southey, Melissa C ^d  

^a CANCER EPIDEMIOLOGY CENTRE   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Human Genetics Foundation   (Italy)

^h Tissupath Pty Ltd   (Australia)

Author keywords

biomarker; DNA methylation; HM450K array; peripheral blood; prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; GENETICS; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK FACTOR;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 85013393349     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23289     Document Type: Article

References (21)

1. Gao Y, Baccarelli A, Shu XO, Ji BT, Yu K, Tarantini L, Yang G, Li HL, Hou L, Rothman N, Zheng W, Gao YT, Chow WH. Blood leukocyte Alu and LINE-1 methylation and gastric cancer risk in the Shanghai Women's Health Study. Br J Cancer 2012; 106(3):585–591.
2. Barry KH, Moore LE, Liao LM, Huang WY, Andreotti G, Poulin M, Berndt SI. Prospective study of DNA methylation at LINE-1 and Alu in peripheral blood and the risk of prostate cancer. Prostate 2015; 75(15):1718–1725.
3. Andreotti G, Karami S, Pfeiffer RM, Hurwitz L, Liao LM, Weinstein SJ, Albanes D, Virtamo J, Silverman DT, Rothman N, Moore LE. LINE1 methylation levels associated with increased bladder cancer risk in pre-diagnostic blood DNA among US (PLCO) and European (ATBC) cohort study participants. Epigenetics 2014; 9(3):404–415.
4. Brennan K, Flanagan JM. Is there a link between genome-wide hypomethylation in blood and cancer risk? Cancer Prev Res 2012; 5(12):1345–1357.
5. Severi G, Southey MC, English DR, Jung CH, Lonie A, McLean C, Tsimiklis H, Hopper JL, Giles GG, Baglietto L. Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res Treat 2014; 148(3):665–673.
6. van Veldhoven K, Polidoro S, Baglietto L, Severi G, Sacerdote C, Panico S, Mattiello A, Palli D, Masala G, Krogh V, Agnoli C, Tumino R, Frasca G, Flower K, Curry E, Orr N, Tomczyk K, Jones ME, Ashworth A, Swerdlow A, Chadeau-Hyam M, Lund E, Garcia-Closas M, Sandanger TM, Flanagan JM, Vineis P. Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics 2015; 7(1):67.
7. Wong Doo N, Makalic E, Joo JE, Vajdic CM, Schmidt DF, Wong EM, Jung CH, Severi G, Park DJ, Chung J, Baglietto L, Prince HM, Seymour JF, Tam C, Hopper JL, English DR, Milne RL, Harrison SJ, Southey MC, Giles GG. Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. Epigenomics 2016; 8(1):55–66.
8. Giles GG, English DR. The melbourne collaborative cohort study. IARC Sci Publ 2002; 156:69–70.
9. Joo JE, Wong EM, Baglietto L, Jung CH, Tsimiklis H, Park DJ, Wong NC, English DR, Hopper JL, Severi G, Giles GG, Southey MC. The use of DNA from archival dried blood spots with the Infinium HumanMethylation450 array. BMC Biotechnol 2013; 13:23.
10. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, Irizarry RA. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 2014; 30(10):1363–1369.
11. Maksimovic J, Gordon L, Oshlack A. SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome Biol 2012; 13(6):R44.
12. Naeem H, Wong NC, Chatterton Z, Hong MK, Pedersen JS, Corcoran NM, Hovens CM, Macintyre G. Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics 2014; 15:51.
13. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8(1):118–127.
14. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39(4):457–466.
15. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, Rosolowski M, Richter J, Lopez-Serra L, Ballestar E, Berger H, Agirre X, Bernd HW, Calvanese V, Cogliatti SB, Drexler HG, Fan JB, Fraga MF, Hansmann ML, Hummel M, Klapper W, Korn B, Kuppers R, Macleod RA, Moller P, Ott G, Pott C, Prosper F, Rosenwald A, Schwaenen C, Schubeler D, Seifert M, Sturzenhofecker B, Weber M, Wessendorf S, Loeffler M, Trumper L, Stein H, Spang R, Esteller M, Barker D, Hasenclever D, Siebert R. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009; 113(11):2488–2497.
16. Price ME, Cotton AM, Lam LL, Farre P, Emberly E, Brown CJ, Robinson WP, Kobor MS. Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. Epigenetics Chromatin 2013; 6(1):4.
17. Marsit CJ, Koestler DC, Christensen BC, Karagas MR, Houseman EA, Kelsey KT. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J Clin Oncol 2011; 29(9):1133–1139.
18. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, Widschwendter M. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS ONE 2009; 4(12):e8274.
19. Harper KN, Peters BA, Gamble MV. Batch effects and pathway analysis: Two potential perils in cancer studies involving DNA methylation array analysis. Cancer Epidemiol Biomarkers Prev 2013; 22(6):1052–1060.
20. Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L, Andriole G, Beane Freeman L, Campa D, Cancel-Tassin G, Canzian F, Cornu JN, Cussenot O, Diver WR, Gapstur SM, Gronberg H, Haiman CA, Henderson B, Hutchinson A, Hunter DJ, Key TJ, Kolb S, Koutros S, Kraft P, Le Marchand L, Lindstrom S, Machiela MJ, Ostrander EA, Riboli E, Schumacher F, Siddiq A, Stanford JL, Stevens VL, Travis RC, Tsilidis KK, Virtamo J, Weinstein S, Wilkund F, Xu J, Lilly Zheng S, Yu K, Wheeler W, Zhang H, Sampson J, Black A, Jacobs K, Hoover RN, Tucker M, Chanock SJ. Two susceptibility loci identified for prostate cancer aggressiveness. Nat Commun 2015; 6:6889.
21. FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, Feng Z, Ostrander EA, Stanford JL. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20(6):1196–1203.